Compare HDRNW & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HDRNW | YDESW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Electric Utilities: Central | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2024 | N/A |
| Metric | HDRNW | YDESW |
|---|---|---|
| Price | $0.14 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 50.8K | 9.9K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.20 |
| 52 Week High | $0.26 | $2.85 |
| Indicator | HDRNW | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 48.51 |
| Support Level | $0.12 | N/A |
| Resistance Level | $0.22 | $0.35 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 53.43 | 60.03 |
Hadron Energy Inc is a nuclear technology company focused on developing factory-fabricated, transportable 10 megawatt-electric (MWe) micro-modular reactors (MMRs) to meet the growing demand for clean, reliable, and affordable power. The company aims to deliver scalable, carbon-free energy solutions that can be rapidly deployed to power a variety of industries, including data centers, industrial facilities, remote communities, government installations and more. The market segments for its proprietary reactor, Hadron Halos, are Data Centers, Industrial Facilities and Heavy Manufacturing, Remote Communities and Critical Infrastructure, and Utilities and Distributed Energy.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.